• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    Trust and the regulation of pharmaceuticals: South Asia in a globalised world. 
    •   QMRO Home
    • Blizard Institute
    • Centre for Primary Care and Public Health
    • Trust and the regulation of pharmaceuticals: South Asia in a globalised world.
    •   QMRO Home
    • Blizard Institute
    • Centre for Primary Care and Public Health
    • Trust and the regulation of pharmaceuticals: South Asia in a globalised world.
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Trust and the regulation of pharmaceuticals: South Asia in a globalised world.

    View/Open
    Published version (369.5Kb)
    Volume
    7
    Pagination
    10 - ?
    DOI
    10.1186/1744-8603-7-10
    Journal
    Global Health
    Metadata
    Show full item record
    Abstract
    BACKGROUND: Building appropriate levels of trust in pharmaceuticals is a painstaking and challenging task, involving participants from different spheres of life, including producers, distributors, retailers, prescribers, patients and the mass media. Increasingly, however, trust is not just a national matter, but involves cross-border flows of knowledge, threats and promises. METHODS: Data for this paper comes from the project 'Tracing Pharmaceuticals in South Asia', which used ethnographic fieldwork and qualitative interviews to compared the trajectories of three pharmaceuticals (Rifampicin, Oxytocin and Fluoxetine) from producer to patient in three sites (north India, West Bengal and Nepal) between 2005-08. RESULTS: We argue that issues of trust are crucial in reducing the likelihood of appropriate use of medicines. Unlike earlier discussions of trust, we suggest that trust contexts beyond the patient-practitioner relationship are important. We illustrate these arguments through three case studies: (i) a conflict over ethics in Nepal, involving a suggested revised ethical code for retailers, medical representatives, producers and prescribers; (ii) disputes over counterfeit, fake, substandard and spurious medicines, and quality standards in Indian generic companies, looking particularly at the role played by the US FDA; and (iii) the implications of lack of trust in the DOTS programmes in India and Nepal for the relationships among patients, government and the private sector. CONCLUSIONS: We conclude that the building of trust is a necessary but always vulnerable and contingent process. While it might be desirable to outline steps that can be taken to build trust, the range of conflicting interests in the pharmaceutical field make feasible solutions hard to implement.
    Authors
    Brhlikova, P; Harper, I; Jeffery, R; Rawal, N; Subedi, M; Santhosh, M
    URI
    http://qmro.qmul.ac.uk/xmlui/handle/123456789/13582
    Collections
    • Centre for Primary Care and Public Health [1467]
    Language
    eng
    Copyright statements
    © Brhlikova et al; licensee BioMed Central Ltd. 2011
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.